Lack of Long-Term Neurologic Efficacy of Zileuton in Sjögren–Larsson's Syndrome

Neuropediatrics 2017; 48(03): 205-206
DOI: 10.1055/s-0037-1601856

Letter to the Editor

Georg Thieme Verlag KG Stuttgart, New York

Catherine Sarret

¹CHU Clermont-Ferrand, Service de Pédiatrie, Hôpital Estaing, Clermont-Ferrand, France

²IGCNC, Université Clermont Auvergne, Clermont-Ferrand, France

,

Samia Pichard

³APHP, Service de Neurologie Pédiatrique et Maladies Métaboliques, Hôpital Robert Debré, Paris, France

,

Alexandra Afenjar

⁴APHP, Service de Neurologie Pédiatrique, Hôpital Armand Trousseau, Paris, France

,

Odile Boespflug-Tanguy

³APHP, Service de Neurologie Pédiatrique et Maladies Métaboliques, Hôpital Robert Debré, Paris, France

⁵Inserm U1141, Université Paris Diderot Sorbonne–Paris Cité, DHU PROJECT, Hôpital Robert Debré, Paris, France

References
1 Rizzo WB. Sjögren-Larsson syndrome: molecular genetics and biochemical pathogenesis of fatty aldehyde dehydrogenase deficiency. Mol Genet Metab 2007; 90 (1) 1-9
2 Willemsen MA, Rotteveel JJ, Steijlen PM, Heerschap A, Mayatepek E. 5-Lipoxygenase inhibition: a new treatment strategy for Sjögren-Larsson syndrome. Neuropediatrics 2000; 31 (1) 1-3
3 Willemsen MA, Lutt MA, Steijlen PM , et al. Clinical and biochemical effects of zileuton in patients with the Sjögren-Larsson syndrome. Eur J Pediatr 2001; 160 (12) 711-717
4 Fuijkschot J, Seyger MM, Bastiaans DE, Wevers RA, Roeleveld N, Willemsen MA. Zileuton for pruritus in Sjögren-Larsson syndrome: a randomized double-blind placebo-controlled crossover trial. Acta Derm Venereol 2016; 96 (2) 255-256
5 Rizzo WB. Genetics and prospective therapeutic targets for Sjögren-Larsson Syndrome. Expert Opin Orphan Drugs 2016; 4 (4) 395-406